In order to improve user experience, ORYX GmbH & Co. KG uses cookies. By continuing to browse this website, you agree to our use of cookies. For further information, please see our Privacy statement.
Accept
Transational Medicine ORYX
Menu
  • Company
    • Team
    • Advisors
    • Contact
  • Development Programs
    • Parvovirus H1
    • Vaccine p16
    • Vaccine MSI
  • Partners
    • Academia
    • Business Development
  • News
    • News
    • Publications
    • Conferences



News

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

11.11.2019 News

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

04.11.2019 News

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

30.10.2019 News

ORYX to Present Positive Clinical Data for Oncolytic Virus ParvOryx in Combination with Immune Modulators at CIMT Annual Meeting 2018

16.05.2018 News

Positive data from Phase I/IIa clinical trial in glioblastoma with oncolytic virus ParvOryx published in peer-reviewed journal, Molecular Therapy

06.11.2017 News

ORYX to present positive clinical data with oncolytic virus ParvOryx in combination with immune activators at the Third CRI-CIMT-EATI-AACR Conference

06.09.2017 News

ORYX reports positive clinical evidence with oncolytic virus ParvOryx in combination with immuno-oncology drugs

23.05.2017 News

partnering360/Informa Pharma Intelligence: Interview with ORYX CEO on research partnerships and cancer vaccine studies

10.05.2016 News

ORYX Enrols First Patients in a Dose-Escalating Phase I/IIa Pilot Study with Oncolytic Virus ParvOryx to Treat Metastatic Pancreatic Cancer

04.04.2016 News

BioCentury: Infectious enthusiasm - How oncolytic viruses are coming of age in cancer immunotherapy combinations

29.02.2016 News

  • Imprint
  • Disclaimer
  • Privacy Statement
  • Contact
  • Sitemap

ORYX I all rights reserved